Skip to main content
SpringerLink
Log in

Diseases of the Liver

Family Medicine

  • 1695 Accesses

Abstract

Diseases of the liver encompass a wide variety of clinical conditions that range from mild abnormalities on liver testing to end-stage liver disease with intrahepatic and extrahepatic manifestations and complications. These also range from acute, self-limited presentations to fulminant disease with rapid liver failure to chronic, low-level disease and also to chronic liver disease that progresses slowly over time. While the history and physical signs of this broad range of clinical disorders are quite similar, often with nonspecific findings with broad-range differentials, laboratory evaluation is critical to sorting through these disease processes. It is critical for family physicians to have an understanding of liver pathology and the laboratory assessment of the hepatic system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286.

    Article  CAS  PubMed  Google Scholar 

  2. Kojaoglanian T. Hepatitis A. Pediatr Rev. 2010;31(8):348–50.

    Article  PubMed  Google Scholar 

  3. Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician. 2012;86(11):1027–34.

    PubMed  Google Scholar 

  4. Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59(8):2223–30.

    CAS  PubMed  Google Scholar 

  5. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1–37.

    Google Scholar 

  6. Updated Recommendations from the ACIP for Use of Hepatitis A Vaccine in Close Contacts of Newly Arriving International Adoptees. MMWR. 2009;58:1–36.

    Google Scholar 

  7. Prevention of Hepatitis A after Exposure to Hepatitis A Virus and in International Travelers: Updated Recommendations of the ACIP. MMWR. 2007;56:1–32.

    Google Scholar 

  8. Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol. 2003;39:S26–30.

    Article  PubMed  Google Scholar 

  9. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225–41.

    Article  CAS  PubMed  Google Scholar 

  10. Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39:S50–8.

    Article  PubMed  Google Scholar 

  11. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.

    Article  Google Scholar 

  12. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010;14:381–96.

    Article  PubMed  Google Scholar 

  13. Hepatitis B vaccination – United States, 1982–2002. MMWR Morb Mortal Wkly Rep. 2002;51:549–52, 563.

    Google Scholar 

  14. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines. MMWR. 2010;59:1–116.

    Google Scholar 

  15. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1. MMWR. 2005;54(RR-16):1–23.

    Google Scholar 

  16. Gitnick G. Non-A, non-B hepatitis: etiology and clinical course. Annu Rev Med. 1984;35:265–78.

    Article  CAS  PubMed  Google Scholar 

  17. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Seef LB. Natural history of hepatitis C. Hepatology. 1997;26 suppl 1:21S–8.

    Article  Google Scholar 

  19. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del Valle Onorato M, Rodes J, Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21(3):639.

    Article  CAS  PubMed  Google Scholar 

  20. Everhart JE, Wright EC, Goodman ZD, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51(2):585–94.

    Article  PubMed  Google Scholar 

  21. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449–57.

    Article  PubMed  Google Scholar 

  22. Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55(1):58–67.

    Article  PubMed  Google Scholar 

  23. AASLD/ISDA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 24 Oct 2014.

  24. Chou R, Barth Cottrell E, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2013;158:101–8.

    Article  PubMed  Google Scholar 

  25. National Institutes of Health. Management of hepatitis C: 2002. National Institutes of Health consensus conference statement. 10–12 June 2002. http://consensus.nih/gov/2002/2002HepatitisC2002116PDF.pdf. Accessed 24 Oct 2014.

  26. Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics. 1998;101(3 Pt1):481–5.

    Google Scholar 

  27. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut. 1997;41:845–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Naveau S, Giraud V, Boretto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108–11.

    Article  CAS  PubMed  Google Scholar 

  29. Cohen SM, Ahn J. Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther. 2009;30(1):3–13.

    Article  CAS  PubMed  Google Scholar 

  30. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637.

    Article  CAS  PubMed  Google Scholar 

  31. Lucey MR, Mathurin P, Morgan TG. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–69.

    Article  CAS  PubMed  Google Scholar 

  32. Moyer VA, Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(3):210–8.

    PubMed  Google Scholar 

  33. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38 Suppl 2:S44–8.

    Article  PubMed  Google Scholar 

  34. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24:483–90.

    Article  CAS  PubMed  Google Scholar 

  35. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41.

    Article  PubMed  Google Scholar 

  36. Benhamou Y, Bochet M, Di Martino V, et al. for the Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999;30:1054–58.

    Google Scholar 

  37. Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209.

    Article  PubMed  Google Scholar 

  38. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C coinfection. Clin Infect Dis. 2005;40:588–93.

    Article  CAS  PubMed  Google Scholar 

  39. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13.

    Article  PubMed  Google Scholar 

  40. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464–73.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883–9.

    Article  CAS  PubMed  Google Scholar 

  42. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2008. http://globocan.iarc.fr. Accessed 17 Oct 2014.

  43. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: incidence – SEER 9 Regs research data, Nov 2009 Sub (1973–2007). Bethesda: National Cancer Institute, April 2010.

    Google Scholar 

  44. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.

    Article  CAS  PubMed  Google Scholar 

  45. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Lok AS, Sterling RK, Everhart JE, HALT-C Trial Group, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.

    Article  PubMed  Google Scholar 

  48. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.

    Article  CAS  PubMed  Google Scholar 

  49. El Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family & Community Medicine, Temple University School of Medicine, 3322 North Broad Street, Medical Office Building – Suite 203, Philadelphia, PA, 19140, USA

    David T. O’Gurek

Authors
  1. David T. O’Gurek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David T. O’Gurek .

Editor information

Editors and Affiliations

  1. Department of Family Medicine, University of Nebraska, Omaha, Nebraska, USA

    Paul Paulman

  2. Virginia Beach, Virginia, USA

    Robert Taylor

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this entry

Cite this entry

O’Gurek, D.T. (2015). Diseases of the Liver. In: Paulman, P., Taylor, R. (eds) Family Medicine. Springer, Cham. https://doi.org/10.1007/978-1-4939-0779-3_97-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Online ISBN: 978-1-4939-0779-3

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Diseases of the Liver
    Published:
    08 October 2020

    DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-2

  2. Original

    Diseases of the Liver
    Published:
    16 April 2015

    DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-1

Search

Navigation